The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ma ...
The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...
Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...